Chul Kim

Also affiliated with Hadassah Medical Center, Georgetown University Medical Center, MedStar Georgetown University Hospital, Georgetown Lombardi Comprehensive Cancer Center

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 16 papers. Top paper: “Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer”.

Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer

Cell Reports Medicine(2020)10.1016/j.xcrm.2020.100007

N/A

5.6DataRank · unranked

182 citations

Anna‐Leigh Brown, Jun S. Wei, Svetlana Pack, Christopher Trindade, Chul Kim +26 more

Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC)

Lung Cancer(2021)10.1016/j.lungcan.2021.08.010

N/A

0.416DataRank · unranked

15 citations

Mohammad Asad, Mohammed Najeeb Al Hallak, Md. Hafiz Uddin, Ammar Sukari, Yasmine Baca +18 more

Osimertinib plus necitumumab in EGFR-mutant NSCLC: Final results from an ETCTN California Cancer Consortium phase I study.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.9014

N/A

0.373DataRank · unranked

11 citations

Mark Krailo, Sukhmani K. Padda, Susan Groshen, Heather A. Wakelee, Karen L. Reckamp +14 more

Whole-exome sequencing reveals germline-mutated small cell lung cancer subtype with favorable response to DNA repair–targeted therapies

Science Translational Medicine(2021)10.1126/scitranslmed.abc7488

N/A

0DataRank · unranked

73 citations

Nobuyuki Takahashi, Lőrinc Sándor Pongor, Vinodh N. Rajapakse, Manoj Tyagi, Xinyu Wen +20 more

Molecular characterization of Kita-Kyushu lung cancer antigen (KK-LC-1) expressing carcinomas.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.e21000

N/A

0DataRank · unranked

0 citations

Yasmine Baca, Joanne Xiu, Rong‐Fu Wang, J. Nicholas Bodor, Chul Kim +8 more

USP13 drives lung squamous cell carcinoma by switching lung club cell lineage plasticity

Molecular Cancer(2023)10.1186/s12943-023-01892-x

N/A

0DataRank · unranked

34 citations

Jinmin Zhang, Boram Mok, Samuel Allsup, Chul Kim, Jeffrey A. Toretsky +2 more

Molecular characterization of nectin-4 in non-small cell lung cancer subtypes.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.e21119

N/A

0DataRank · unranked

2 citations

Nishant Gandhi, Chul Kim, Hirva Mamdani, Balázs Halmos, Ari M. Vanderwalde +5 more

Supplementary Figure S3 from Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes

(2023)10.1158/1078-0432.22478576

N/A

0DataRank · unranked

0 citations

Anh T. Le, Andrea E. Doak, Vijaya G. Tirunagaru, Shevan Silva, Matthew R. Bull +6 more

Data from Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes

(2023)10.1158/1078-0432.c.6529985

N/A

0DataRank · unranked

0 citations

Anh T. Le, Andrea E. Doak, Vijaya G. Tirunagaru, Shevan Silva, Matthew R. Bull +6 more

Data from Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes

(2023)10.1158/1078-0432.c.6529985.v1

N/A

0DataRank · unranked

0 citations

Anh T. Le, Andrea E. Doak, Vijaya G. Tirunagaru, Shevan Silva, Matthew R. Bull +6 more

Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States

Clinical Lymphoma Myeloma & Leukemia(2024)10.1016/j.clml.2024.03.011

N/A

0DataRank · unranked

15 citations

Talal El Zarif, Ramya Ramaswami, Amin H. Nassar, Elio Adib, Noha Abdel‐Wahab +25 more

Corrigendum to 'Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States' [Clinical Lymphoma, Myeloma, and Leukemia Volume 24, Issue 8, August 2024, Pages 523-530]

Clinical Lymphoma Myeloma & Leukemia(2024)10.1016/j.clml.2024.10.011

N/A

0DataRank · unranked

0 citations

Talal El Zarif, Ramya Ramaswami, Amin H. Nassar, Elio Adib, Noha Abdel‐Wahab +25 more

Characteristics, treatment patterns, and outcomes of HIV-associated lung cancer.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.16_suppl.8050

N/A

0DataRank · unranked

0 citations

Ujjwal Karki, Tianzhi Tang, Anya Gupta, Kanchi Krishnamurthy, Camelia Bencheqroun +13 more

Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States

UNC Libraries(2025)10.17615/bc35-y591

N/A

0DataRank · unranked

0 citations

Praful Ravi, Robert A. Baiocchi, Noha Abdel‐Wahab, Swetha Kambhampati, Talal El Zarif +25 more

Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-3555

N/A

0DataRank · unranked

81 citations

Anh T. Le, Andrea E. Doak, Vijaya G. Tirunagaru, Shevan Silva, Matthew R. Bull +6 more

Longitudinal Monitoring of EGFR and PIK3CA Mutations by Saliva-Based EFIRM in Advanced NSCLC Patients With Local Ablative Therapy and Osimertinib Treatment: Two Case Reports

Frontiers in Oncology(2020)10.3389/fonc.2020.01240

N/A

0DataRank · unranked

12 citations

Udayan Guha, Chul Kim, Leah Ye, Jordan Cheng, Feng Li +4 more